A Glucose Trace Is Not a Diagnosis
Continuous glucose monitoring (CGM) is increasingly being used by people who do not have a diabetes diagnosis. The subject is not simply whether a sensor can produce more readings; it is what CGM-derived glucose data can legitimately describe in these people, what those patterns may be related to, and what action or clinical conclusion the evidence can support. The useful judgment is therefore not “Does this number look normal?” but “What question does this measurement answer?”
That distinction matters because a CGM trace feels unusually personal. It moves with meals, sleep, activity, and ordinary routines, so it can appear to reveal the body in real time. A continuous record does provide information that an isolated laboratory value cannot. But a vivid signal can still be overinterpreted. More observations do not automatically create a diagnosis, prove a cause, or guarantee that changing a behavior will change body weight.
Two recent studies illustrate both sides of the subject. One examines how glucose dynamics can be represented in people without diagnosed diabetes and how those dynamics relate to early vascular, liver, and insulin-related markers. The other reviews whether using CGM in non-diabetic populations improves glycemic, behavioral, or weight outcomes. Together they support a bounded view: CGM can be a rich description of glucose behavior and a useful feedback tool, but its meaning depends on the question, the context, and the evidence behind the conclusion.
A stream answers a different question from a snapshot
A fasting glucose value asks about glucose under a particular condition. A two-hour postprandial value asks what remains after a standardized interval following a meal or glucose challenge. HbA1c summarizes longer-term average exposure. These measures are not obsolete because CGM exists; each is designed to answer a narrower and often clinically important question.
CGM adds a time series. Instead of seeing only selected points, researchers can examine how high glucose tends to run, how widely it fluctuates, and how one reading relates to readings that came shortly before it. Those differences can matter even when two people have similar average glucose. One person may have a relatively even trace. Another may have the same average built from larger swings or a different temporal pattern. A single average cannot preserve all of that information.
The distinction is especially important before diabetes is diagnosed. Early changes in glucose regulation may not appear as a decisive abnormality in a conventional snapshot, while a longer record can reveal differences between people. The full-text study on non-diabetic populations argues that fasting glucose, two-hour postprandial glucose, and mean glucose mainly occupy a one-dimensional space dominated by average level. The broader CGM record contains other dimensions of variation.
That does not mean every excursion is meaningful. A trace is still a measurement made over a particular window, with a particular device, sampling process, and surrounding behavior. A high point may be a real reading without explaining whether the cause was a meal, timing, physiology, or measurement context. The advantage of a trajectory is that it gives researchers more structure to analyze—not that it removes the need for interpretation.
Four jobs, four standards
The same CGM trace can be asked to do at least four different jobs. Keeping them separate is the simplest protection against both hype and dismissal.
First, description. A CGM record can describe a person’s glucose dynamics over a chosen period. It can show average level, variation, and temporal structure. This is the most direct claim because it stays close to the data: these readings behaved in this way under these conditions.
Second, research stratification. Researchers may use those features to place participants into groups or examine whether a pattern is associated with another measure. A 2026 study analyzed CGM data from 8,025 adults without diagnosed diabetes. Its analyses identified three broad axes—mean, variance-related measures, and autocorrelation-related measures—that explained most of the observed differences among the CGM metrics. In a separate analysis of 1,784 non-diabetic adults, the selected features were associated with measures of carotid artery structure and liver tissue, as well as with insulin-related measures in other datasets.
That is scientifically important, but “associated with” has a precise meaning. It says that two measured features vary together after the study’s analysis; it does not say that one caused the other. It does not establish that a particular person has vascular disease, fatty liver, impaired insulin clearance, or any other condition because their trace resembles a research pattern. The study itself notes that no CGM-based diagnostic criteria have been established.
Third, structured lifestyle feedback. CGM can make a response visible while someone is participating in a program intended to change diet or other behavior. The systematic review of non-diabetic populations included 23 studies and 1,074 participants across 11 countries. Its abstract reports a significant improvement in mean blood glucose compared with controls, along with higher behavioral adherence and specific dietary modifications in the qualitative evidence. This supports a feedback role: information may help connect a choice with a subsequent response and make an intervention more concrete.
Feedback is not the same as diagnosis. Nor is it the same as a guaranteed outcome. A program can use a signal to guide action without proving that the signal identified a specific physiological defect. The review’s conclusion is correspondingly narrow: CGM is best positioned as a precision biofeedback tool integrated into a structured lifestyle program.
Fourth, clinical diagnosis. Diagnosis requires an appropriate clinical framework, validated criteria, and evidence that a test performs reliably for the intended decision. A continuously changing line on a screen does not supply those things by itself. The absence of established CGM-based diabetes diagnostic criteria is not a minor footnote. It tells us that the data may be promising for describing and researching glucose regulation while remaining insufficient as a standalone diagnostic verdict.
These four jobs can coexist in one project, but they cannot borrow each other’s authority. A descriptive result cannot become a diagnosis merely because it is detailed. An association cannot become a treatment recommendation merely because it is biologically plausible. A behavior change observed in a study cannot become a promise for every sensor wearer.
Why the boundary changes the meaning of a reading
Consider two people who see an unusual post-meal rise. The trace may be worth examining, but the first responsible question is not whether either person has diabetes. It is what was measured and what conclusion is being attempted. Was the pattern repeated across a sufficiently continuous recording? Was the meal comparable? Is the question about describing a response, changing a dietary behavior, understanding research risk, or deciding whether clinical testing is needed?
The answer also depends on the population. The systematic review reports improved glycemic control in people with prediabetes but no appreciable glycemic benefit in healthy normoglycemic populations. That contrast does not mean a sensor is valuable for one group and useless for the other in every circumstance. It does mean that baseline condition and available room for change affect applicability. Evidence from a person with prediabetes participating in a structured intervention should not be silently generalized to a healthy person seeking a reassuring score.
The same caution applies to weight. The review found no significant difference in body mass index: the standardized mean difference was −0.25, with a 95% confidence interval from −0.63 to 0.12 and P = 0.19. The practical conclusion is not that CGM can never appear in a successful weight program. It is that sensor wear alone is unlikely to achieve weight-management goals. Seeing a glucose response may support a short-term dietary choice; it does not supply all the mechanisms required for a sustained change in body weight.
The first study adds another boundary. Its three-feature representation reconstructed postprandial patterns well in controlled analyses, but its real-life reconstruction was less exact. Everyday records contain closely spaced meals, uncertain meal timing, and other complexity that a standardized challenge controls. The authors also note that the autocorrelation-based feature requires densely sampled, contiguous data and that a multi-day window is part of the analysis. A short or interrupted trace should not be treated as equivalent to the research record simply because both are labeled CGM.
So the central lesson is not to distrust the trace. It is to match the strength of the conclusion to the strength of the evidence. A CGM record may tell us that glucose varied in a particular way. A research analysis may show that such variation is associated with a marker. A structured intervention may show that feedback can support certain behaviors. None of those statements, alone, answers the diagnostic question.
A useful reading habit follows from this distinction: before reacting to a number, name the job. If the job is description, describe the pattern. If it is research stratification, ask what outcome was measured and whether the association was observational. If it is behavior feedback, ask what program surrounds the sensor and which outcome actually changed. If it is diagnosis, recognize that additional clinical evidence is required.
That is why a glucose trace is more than a number, but less than a verdict. Its value lies in the dimensions and relationships it can make visible. Its limits lie in the context that produced those readings and in the distance between observing a pattern and knowing what it means for one person.